Medical Marijuana Inc (MJNA)

[@LaughinPaulRyan]

... Derivatively Yes ...

KannaLife is a late stage bio-pharmaceutical and phyto-medical company that specializes in the research and development (R&D) of pharmacological products derived from plants. The company announced in July of 2012, that it had signed an exclusive license agreement with the "National Institutes of Health - Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent 6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent")" to focus on Hepatic Encephalopathy (HE) which is associated with reduced brain function due to various forms of liver toxicity.

Michelle Sexton, ND – Scientific Advisory Board

Dr. Sexton is a renowned Naturopathic Doctor (“ND”), Assistant Research Professor and Adjunct Faculty at Bastyr University in Seattle, WA where she also has a private practice. She has co-authored several peer reviewed scientific research articles including “NIR-mbc94, a fluorescent ligand that binds to endogenous CB(2) receptors and is amenable to high-throughput screening” Dr. Sexton’s research on CB2 receptor imaging will play an important role in the R&D of KannaLife’s target drug candidate. Dr. Sexton received her Bachelor of Science in Horticulture from Texas Tech University and her Doctorate in Naturopathic Medicine from Bastyr University. She was previously a midwife and herbalist and has an enduring passion for phytochemicals and their biological effects. She is a member of the American Association of Naturopathic Physicians, Society for Orthomolecular Medicine, the International Cannabinoid Research Society the International Association for Cannabis as Medicine and the Society of Cannabis Clinicians. Dr. Sexton recently completed an individual postdoctoral fellowship (F32) from NIH/NCCAM in the Departments of Pharmacology and Psychiatry and Behavioral Medicine at the University of Washington, where she specialized in the endogenous cannabinoid signaling system and its’ role in neuroinflammation and neurodegeneration.



As KannaLife progresses its drug development, it is also taking steps to provide commercial and regulatory guidance and practices for producing and certifying organic botanical medicaments. Under Kannalife’s certification program it will seek to ensure it and others who subscribe and utilize Kannalife’s quality control (QC) and quality assurance (QA) protocols and processes does so to manufacture and sell quality products that can meet or exceed the standardization controls found in FDA’s Guidance for Industry Botanical Drug Products (June 2004). 

KannaLife has assembled what looks to be a very strong advisory board as well as a team of well regarded scientific professionals with strong pharmaceutical experience. Through South Park Ventures LLC, KannaLife has positioned itself to provide expertise in efficacy and standardization of product development.